In summary, we demonstrate that the clinical-grade cell-penetrating peptide CIGB-300 is able to block proliferation and induce cell death of both cell lines and primary T-ALL patient cells, even in the presence of leukemia-supportive signals such as IL-7 or stromal cell co-culture. This evidence concerns the gene IL7 and leukemia.